等待開盤 11-19 09:30:00 美东时间
-0.205
-0.43%
Agreement paves the way for newly diagnosed, transplant-ineligible patients fighting multiple myeloma to access first-line treatment Sarclisa® through provincial and territorial cancer treatment formulary listings.
11-16 22:16
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
07-25 02:10
The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc) Escena in combination with standard-of-care regimens for the treatment of patients with multiple myeloma (MM) across
07-10 20:55
Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth up to $2.1 billion.
07-08 22:14
EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany and France.
06-29 23:44
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.
06-24 00:21
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.
06-16 01:15
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
06-11 21:09
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.
06-05 19:01